WO2001060991A3 - Human kinases - Google Patents

Human kinases Download PDF

Info

Publication number
WO2001060991A3
WO2001060991A3 PCT/US2001/005240 US0105240W WO0160991A3 WO 2001060991 A3 WO2001060991 A3 WO 2001060991A3 US 0105240 W US0105240 W US 0105240W WO 0160991 A3 WO0160991 A3 WO 0160991A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkin
human kinases
provides
kinases
polynucleotides
Prior art date
Application number
PCT/US2001/005240
Other languages
French (fr)
Other versions
WO2001060991A2 (en
Inventor
Y Tom Tang
Neil Buford
Ameena R Gandhi
Chandra Patterson
Farrah A Khan
Henry Yue
April Hafalia
Leo L Shih
Catherine M Tribouley
Monique G Yao
John D Burrill
Gregory A Marcus
Kurt A Zingler
Dyung Aina M Lu
Olga Bandman
Jennifer L Policky
Jennifer A Griffin
Michael Thornton
Danniel B Nguyen
Preeti Lal
Roderick T Walsh
Original Assignee
Incyte Genomics Inc
Y Tom Tang
Neil Buford
Ameena R Gandhi
Chandra Patterson
Farrah A Khan
Henry Yue
April Hafalia
Leo L Shih
Catherine M Tribouley
Monique G Yao
John D Burrill
Gregory A Marcus
Kurt A Zingler
Dyung Aina M Lu
Olga Bandman
Jennifer L Policky
Jennifer A Griffin
Michael Thornton
Danniel B Nguyen
Preeti Lal
Roderick T Walsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Y Tom Tang, Neil Buford, Ameena R Gandhi, Chandra Patterson, Farrah A Khan, Henry Yue, April Hafalia, Leo L Shih, Catherine M Tribouley, Monique G Yao, John D Burrill, Gregory A Marcus, Kurt A Zingler, Dyung Aina M Lu, Olga Bandman, Jennifer L Policky, Jennifer A Griffin, Michael Thornton, Danniel B Nguyen, Preeti Lal, Roderick T Walsh filed Critical Incyte Genomics Inc
Priority to CA002400034A priority Critical patent/CA2400034A1/en
Priority to EP01910933A priority patent/EP1255819A2/en
Priority to JP2001560362A priority patent/JP2004502404A/en
Priority to AU2001238488A priority patent/AU2001238488A1/en
Publication of WO2001060991A2 publication Critical patent/WO2001060991A2/en
Publication of WO2001060991A3 publication Critical patent/WO2001060991A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.
PCT/US2001/005240 2000-02-17 2001-02-16 Human kinases WO2001060991A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002400034A CA2400034A1 (en) 2000-02-17 2001-02-16 Human kinases
EP01910933A EP1255819A2 (en) 2000-02-17 2001-02-16 Human kinases
JP2001560362A JP2004502404A (en) 2000-02-17 2001-02-16 Human kinase
AU2001238488A AU2001238488A1 (en) 2000-02-17 2001-02-16 Human kinases

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US18368200P 2000-02-17 2000-02-17
US60/183,682 2000-02-17
US18655900P 2000-03-02 2000-03-02
US60/186,559 2000-03-02
US18860600P 2000-03-09 2000-03-09
US60/188,606 2000-03-09
US18999800P 2000-03-17 2000-03-17
US60/189,998 2000-03-17
US19385100P 2000-03-30 2000-03-30
US60/193,851 2000-03-30

Publications (2)

Publication Number Publication Date
WO2001060991A2 WO2001060991A2 (en) 2001-08-23
WO2001060991A3 true WO2001060991A3 (en) 2002-03-21

Family

ID=27539107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005240 WO2001060991A2 (en) 2000-02-17 2001-02-16 Human kinases

Country Status (5)

Country Link
EP (1) EP1255819A2 (en)
JP (1) JP2004502404A (en)
AU (1) AU2001238488A1 (en)
CA (1) CA2400034A1 (en)
WO (1) WO2001060991A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US6242419B1 (en) * 1999-03-25 2001-06-05 Genesis Research & Development Corporation Ltd. Compositions isolated from stromal cells and methods for their use
AU2001245974A1 (en) * 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
EP1341906A2 (en) 2000-12-11 2003-09-10 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
ATE483976T1 (en) * 2001-06-05 2010-10-15 Exelixis Inc GFATS AS P53 PATHWAY MODIFIERS AND METHODS OF USE
DK2325302T3 (en) * 2003-02-11 2016-03-14 Shire Human Genetic Therapies Cells expressing a sulfatase and a C-formylglycine-generating enzyme and methods and uses thereof
AU2012206984B2 (en) * 2003-02-11 2015-07-09 Takeda Pharmaceutical Company Limited Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE)
WO2004072277A2 (en) * 2003-02-13 2004-08-26 Asahi Kasei Pharma Corporation Elk1 phosphorylation related genes
WO2010022444A1 (en) * 2008-08-25 2010-03-04 The Walter And Eliza Hall Institute Of Medical Research Methods and agents for modulating kinase signalling pathways through modulation of mixed-lineage kinase domain-like protein (mlkl)
EP2243828A1 (en) * 2009-04-24 2010-10-27 DKFZ Deutsches Krebsforschungszentrum Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
CN109071634A (en) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 Antibody coupling matter and its preparation and application
EP3678685A1 (en) 2017-09-07 2020-07-15 Vib Vzw Mixed-lineage kinase domain-like protein in immunotherapeutic cancer control

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001756A1 (en) * 1996-07-09 1998-01-15 Washington University DNA SEQUENCES ENCODING HUMAN TcAK1 KINASE
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
WO1999047686A2 (en) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
WO2000073469A2 (en) * 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001756A1 (en) * 1996-07-09 1998-01-15 Washington University DNA SEQUENCES ENCODING HUMAN TcAK1 KINASE
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
WO1999047686A2 (en) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
WO2000073469A2 (en) * 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
EP1074617A2 (en) * 1999-07-29 2001-02-07 Helix Research Institute Primers for synthesising full-length cDNA and their use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 November 1998 (1998-11-01), XP002178443, Database accession no. O75460 *
DATABASE EMBL [online] 1 October 2000 (2000-10-01), XP002178444, Database accession no. Q9P2I7 *
DATABASE EMBL [online] 14 June 2001 (2001-06-14), XP002178446, Database accession no. BAB55194 *
DATABASE EMBL [Online] 26 June 2001 (2001-06-26) Database accession nos.: AAH06691; AAH13724; AAH14480; AAH17672;AAH18549. *
DATABASE EMBL [online] 29 September 2000 (2000-09-29), XP002178445, Database accession no. AK024274 *
HANKS S K: "HOMOLOGY PROBING: IDENTIFICATION OF CDNA CLONES ENCODING MEMBERS OFTHE PROTEIN-SERINE KINASE FAMILY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 84, January 1987 (1987-01-01), pages 388 - 392, XP000941941, ISSN: 0027-8424 *
ROSOK OYSTEIN ET AL: "Identification and characterization of TESK2, a novel member of the LIMK/TESK family of protein kinases, predominantly expressed in testis.", GENOMICS, vol. 61, no. 1, 1 October 1999 (1999-10-01), pages 44 - 54, XP002178442, ISSN: 0888-7543 *
TAKAHASHI M ET AL: "RET TRANSFORMING GENE ENCODES A FUSION PROTEIN HOMOLOGOUS TO TYROSINE KINASES", MOLECULAR AND CELLULAR BIOLOGY, vol. 7, no. 4, 1987, pages 1378 - 1385, XP001027825, ISSN: 0270-7306 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof

Also Published As

Publication number Publication date
AU2001238488A1 (en) 2001-08-27
CA2400034A1 (en) 2001-08-23
WO2001060991A2 (en) 2001-08-23
JP2004502404A (en) 2004-01-29
EP1255819A2 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
WO2001098468A3 (en) Proteases
WO2003052075A3 (en) Enzymes
WO2001096547A3 (en) Human kinases
WO2002018557A3 (en) Human kinases
WO2001060991A3 (en) Human kinases
WO2002008396A3 (en) Human proteases
WO2003033680A3 (en) Kinases and phosphatases
WO2001051638A3 (en) Drug metabolizing enzymes
WO2002083709A3 (en) Kinases and phosphatases
WO2001046397A3 (en) Human kinases
WO2001090334A3 (en) Drug metabolizing enzymes
WO2002004612A3 (en) Drug metabolizing enzymes
WO2001072777A3 (en) Human transcription factors
WO2002038744A3 (en) Proteases
WO2003042357A3 (en) Enzymes
WO2001098471A8 (en) Human phosphodiesterases
WO2002026950A3 (en) Transferases
WO2001096546A3 (en) Protein phosphatases
WO2001071004A3 (en) Proteases
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2001081555A3 (en) Human kinases
WO2002033099A3 (en) Human kinases
WO2002020736A3 (en) Proteases
WO2001079468A3 (en) Drug metabolizing enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2400034

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 560362

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001910933

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910933

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001910933

Country of ref document: EP